Work

Abstract CT095: A Phase Ib/IIa study of the BET bromodomain inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

Year: 2019

Type: conference-abstract

Source: Clinical Trials

DOI: 10.1158/1538-7445.sabcs18-ct095

Authors: Rahul Aggarwal, Wassim Abida, Michael Schweizer, Allan Pantuck, David Nanus, Elisabeth Heath, Sanjay Lakhotia, Henrik Hansen, Michael Silverman, Lisa Bauman, Margo Snyder, Eric Campeau, Karen Norek, Sarah Attwell, Marie O'Farrell, Steve Smith, Philip Wegge, Ravi Jahagirdar, Joshi Alumkal

Institutions: University of California, San Francisco, Memorial Sloan Kettering Cancer Center, University of Washington, University of California, Los Angeles, Weill Cornell Medical Center, The Barbara Ann Karmanos Cancer Institute, Oregon Health & Science University

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4241362997

Cites:

Cited by: 2

Related to: 10